Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Immunologic Research
Erschienen in: Immunologic Research 1-3/2013

01.12.2013 | Immunology & Microbiology in Miami

New therapeutic approaches for protecting hematopoietic stem cells in aplastic anemia

verfasst von: Wendy Weston, Vineet Gupta, Rebecca Adkins, Roland Jurecic

Erschienen in: Immunologic Research | Ausgabe 1-3/2013

Einloggen, um Zugang zu erhalten

Abstract

Aplastic anemia (AA) is an immune-mediated and life-threatening form of acquired bone marrow failure (BMF), characterized by development and expansion of self-reactive T cells. These T cells cause continuous destruction of hematopoietic stem cells (HSCs), progenitors, and mature blood cells, leading to severe and if left untreated fatal marrow hypoplasia and pancytopenia. Standard treatment options for patients with AA include: (1) immunosuppressive therapy (IST) with anti-thymocyte globulin and cyclosporine A which targets self-reactive T cells, or (2) matched sibling or unrelated BM transplant (BMT). The IST treatment is often not effective due to poor response to therapy or disease relapse after IST. Also, BMT is not an option for many patients due to their age, comorbidities, and the lack of histocompatible donor. This necessitates development and testing of novel approaches to reduce severity of AA and to efficiently treat patients with refractory and relapsed AA. Immune-mediated AA was reproduced in animals, including mouse lymphocyte infusion models, which are used to study further etiology and pathophysiology of AA and test new drugs and approaches in treating and managing AA. In these mouse models the immune correlates and pathologic features of AA are strikingly similar to features of severe human AA. In this article we (a) briefly review standard and developing approaches for treating AA and (b) describe development and testing of novel treatment approach with a potential to safely reduce BM hypoplasia and significantly decrease the loss of HSCs in mouse lymphocyte infusion model of AA.
Literatur
1.
Young NS, editor. Bone marrow failure syndromes. Philadelphia: WB Saunders; 2000.
2.
Li JP, Zheng CL, Han ZC. Abnormal immunity and stem/progenitor cells in acquired aplastic anemia. Crit Rev Oncol Hematol. 2010;75:79–93.CrossRefPubMed
3.
4.
Young NS, Kaufman DW. The epidemiology of acquired aplastic anemia. Haematologica. 2008;93:489–92.CrossRefPubMed
5.
Risitano AM, Maciejewski JP, Green S, Plasilova M, Zeng W, Young NS. In-vivo dominant immune responses in aplastic anaemia: molecular tracking of putatively pathogenetic T-cell clones by TCR beta-CDR3 sequencing. Lancet. 2004;364:355–64.CrossRefPubMed
6.
7.
Segel GB, Lichtman MA (2010). Aplastic anemia: acquired and Inherited, Chapter 34. In Williams Hematology, Eighth Edition. McGraw-Hill 2010.
8.
Fliedner TM, et al. Structure and function of bone marrow hemopoiesis: mechanisms of response to ionizing radiation exposure. Cancer Biother Radiopharm. 2002;17:405–26.CrossRefPubMed
9.
Meng A, Wang Y, Van Zant G, Zhou D. Ionizing radiation and busulfan induce premature senescence in murine bone marrow hematopoietic cells. Cancer Res. 2003;63:5414–9.PubMed
10.
Meng A, Wang Y, Brown SA, Van Zant G, Zhou D. Ionizing radiation and busulfan inhibit murine bone marrow cell hematopoietic function via apoptosis-dependent and -independent mechanisms. Exp Hematol. 2003;31:1348–56.CrossRefPubMed
11.
Bagby GC, Meyers G. Myelodysplasia and acute leukemia as late complications of marrow failure: future prospects for leukemia prevention. Hematol Oncol Clin North Am. 2009;23:361–76.PubMedCentralCrossRefPubMed
12.
Bagby GC, Meyers G. Bone marrow failure syndromes. Preface. Hematol Oncol Clin North Am. 2009;23:8–14.
13.
Myers KC, Davies SM. Hematopoietic stem cell transplantation for bone marrow failure syndromes in children. Biol Blood Marrow Transplant. 2009;15:279–92.CrossRefPubMed
14.
Peinemann F, Grouven U, Kröger N, Pittler M, Zschorlich B, Lange S. Unrelated donor stem cell transplantation in acquired severe aplastic anemia: a systematic review. Haematologica. 2009;94:1732–42.PubMedCentralCrossRefPubMed
15.
Risitano AM. Immunosuppressive therapies in the management of acquired immune-mediated marrow failures. Curr Opin Hematol. 2012;19:3–13.CrossRefPubMed
16.
Marsh JC, et al. Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol. 2009;147:43–70.CrossRefPubMed
17.
18.
Afable MG 2nd, Tiu RV, Maciejewski JP. Clonal evolution in aplastic anemia. Hematol Am Soc Hematol Educ Program. 2011;2011:90–5.CrossRef
19.
Afable MG 2nd, et al. SNP array-based karyotyping: differences and similarities between aplastic anemia and hypocellular myelodysplastic syndromes. Blood. 2011;117:6876–84.PubMedCentralCrossRefPubMed
20.
Risitano AM, et al. Working Party Severe Aplastic Anaemia (WPSAA) of the European Group for Blood and Marrow Transplantation (EBMT). Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure: a pilot study and a survey from the EBMT WPSAA. Br J Haematol. 2010;148:791–6.CrossRefPubMed
21.
Piccin A, et al. Aplastic Anaemia Working Party of the European Group for Blood and Marrow Transplantation. Survival of patients with documented autologous recovery after SCT for severe aplastic anemia: a study by the WPSAA of the EBMT. Bone Marrow Transplant. 2010;45:1008–13.CrossRefPubMed
22.
Bacigalupo A, et al. Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation. Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA Working Party. Haematologica. 2010;95:976–82.PubMedCentralCrossRefPubMed
23.
Marsh J, et al. European Group for Blood and Marrow Transplantation (EBMT) Severe Aplastic Anaemia Working Party. Should irradiated blood products be given routinely to all patients with aplastic anaemia undergoing immunosuppressive therapy with antithymocyte globulin (ATG)? A survey from the European Group for Blood and Marrow Transplantation Severe Aplastic Anaemia Working Party. Br J Haematol. 2010;150:377–9.PubMedCentralCrossRefPubMed
24.
25.
Pulsipher MA, et al. Optimization of therapy for severe aplastic anemia based on clinical, biologic, and treatment response parameters: conclusions of an international working group on severe aplastic anemia convened by the Blood and Marrow Transplant Clinical Trials Network, March 2010. Biol Blood Marrow Transplant. 2011;17:291–9.PubMedCentralCrossRefPubMed
26.
27.
Barnes DWH, Mole RH. Aplastic anaemia in sublethally irradiated mice given allogeneic lymph node cells. Br J Haematol. 1967;13:482–91.CrossRefPubMed
28.
Morley A, Blake J. An animal model of chronic aplastic marrow failure, I: late marrow failure after busulfan. Blood. 1974;4:49–56.
29.
Knospe WH, Steinberg D, Speck B. Experimental immunologically mediated aplastic anemia (AA) in H-2 k identical, mLs (M) locus different mice. Exp Hematol. 1983;11:542–52.PubMed
30.
Knospe WH, Steinberg D, Gratwohl A, Speck B. Experimental immunologically mediated aplastic anemia (AA) in mice: cyclosporin A fails to protect against AA. Int J Cell Cloning. 1984;2:263–71.CrossRefPubMed
31.
Chiu KM, Knospe WH. Immunologically mediated aplastic anemia in mice: effects of varying the source and composition of donor cells. Exp Hematol. 1987;15:269–75.PubMed
32.
Hayashi NM, Abe F, Takita T, Nakamura T, Takeuchi T, Umezawa H. Therapy of experimental immunologically mediated aplastic anemia in mice by various immunosuppressive and antitumor agents. Transplant Proc. 1988;20:545–8.PubMed
33.
Knospe WH, Husseini SG, Chiu KM, Fried W. Immunologically mediated aplastic anemia in mice: evidence of hematopoietic stromal injury and injury to hematopoietic stem cells. Exp Hematol. 1994;22:573–81.PubMed
34.
Bloom ML, et al. A mouse model of lymphocyte infusion-induced bone marrow failure. Exp Hematol. 2004;32:1163–72.CrossRefPubMed
35.
36.
37.
Broomhall KS, Morin M, Pevear DC, Pfau CJ. Severe and transient pancytopenia associated with a chronic arenavirus infection. J Exp Pathol. 1987;3:259–69.PubMed
38.
Stellrecht-Broomhall KA. Evidence for immune-mediated destruction as mechanism for LCMV-induced anemia in persistently infected mice. Viral Immunol. 1991;4:269–820.CrossRefPubMed
39.
Mayer A, Podlech J, Kurz S, Steffens HP, Maiberger S, Thalmeier K, Angele P, Dreher L, Reddehase MJ. Bone marrow failure by cytomegalovirus is associated with an in vivo deficiency in the expression of essential stromal hemopoietin genes. J Virol. 1997;71:4589–98.PubMedCentralPubMed
40.
Binder D, van den Broek MF, Kägi D, Bluethmann H, Fehr J, Hengartner H, Zinkernagel RM. Aplastic anemia rescued by exhaustion of cytokine-secreting CD8+T cells in persistent infection with lymphocytic choriomeningitis virus. J Exp Med. 1998;187:1903–20.PubMedCentralCrossRefPubMed
41.
Binder D, Fehr J, Hengartner H, Zinkernagel RM. Virus-induced transient bone marrow aplasia: major role of interferon-alpha/beta during acute infection with the noncytopathic lymphocytic choriomeningitis virus. J Exp Med. 1997;185:517–30.PubMedCentralCrossRefPubMed
42.
Chen J, et al. Bystander destruction of hematopoietic progenitor and stem cells in a mouse model of infusion-induced bone marrow failure. Blood. 2004;104:1671–8.CrossRefPubMed
43.
Turton JA, et al. Further development of a model of chronic bone marrow aplasia in the busulphan-treated mouse. Int J Exp Pathol. 2006;87(4):9–63.
44.
Chen J, Ellison FM, Eckhaus MA, Smith AL, Keyvanfar K, Calado RT, Young NS. Minor antigen h60-mediated aplastic anemia is ameliorated by immunosuppression and the infusion of regulatory T cells. J. Immunol. 2007;178:4159–68.CrossRefPubMed
45.
Sarcon AK, Desierto MJ, Zhou W, Visconte V, Gibellini F, Chen J, Young NS. Role of perforin-mediated cell apoptosis in murine models of infusion-induced bone marrow failure. Exp Hematol. 2009;37:477–86.PubMedCentralCrossRefPubMed
46.
Tang Y, Desierto MJ, Chen J, Young NS. The role of the Th1 transcription factor T-bet in a mouse model of immune-mediated bone-marrow failure. Blood. 2010;115:541–8.PubMedCentralCrossRefPubMed
47.
48.
Qiao X, Xie X, Jiang S, Shi W, Tang J, Zhou N. Experimental bone marrow failure in mice ameliorated by OCH via tippling the balance of released cytokines from Th1 to Th2. Immunopharmacol Immunotoxicol. 2012;34:491–8.CrossRefPubMed
49.
Maciejewski J, Selleri C, Anderson S, Young NS. Fas antigen expression on CD34+ human marrow cells is induced by interferon gamma and tumor necrosis factor alpha and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood. 1995;85:3183–90.PubMed
50.
Erie AJ, et al. MHC class II upregulation and colocalization with Fas in experimental models of immune-mediated bone marrow failure. Exp Hematol. 2011;39:837–49.PubMedCentralCrossRefPubMed
51.
Roderick JE, et al. Therapeutic targeting of NOTCH signaling ameliorates immune-mediated bone marrow failure of aplastic anemia. J Exp Med. 2013;210:1311–29.PubMedCentralCrossRefPubMed
52.
53.
Mayadas TN, Cullere X. Neutrophil beta2 integrins: moderators of life or death decisions. Trends Immunol. 2005;26:388–95.CrossRefPubMed
54.
Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol. 2007;7:678–89.CrossRefPubMed
55.
56.
Kubota Y, Takubo K, Shimizu T, Ohno H, Kishi K, Shibuya M, et al. M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis. J Exp Med. 2009;206:1089–102.PubMedCentralCrossRefPubMed
57.
Arnaout MA. Leukocyte adhesion molecules deficiency: its structural basis, pathophysiology and implications for modulating the inflammatory response. Immunol Rev. 1990;114:145–80.CrossRefPubMed
58.
Phillipson M, Heit B, Colarusso P, Liu L, Ballantyne CM, Kubes P. Intraluminal crawling of neutrophils to emigration sites: a molecularly distinct process from adhesion in the recruitment cascade. J Exp Med. 2006;203:2569–75.PubMedCentralCrossRefPubMed
59.
Varga G, et al. Active MAC-1 (CD11b/CD18) on DCs inhibits full T-cell activation. Blood. 2007;109:661–9.CrossRefPubMed
60.
Bai Y, Qian C, Qian L, Ma F, Hou J, Chen Y, Wang Q, Cao X. Integrin CD11b negatively regulates TLR9-triggered dendritic cell cross-priming by upregulating microRNA-146a. J Immunol. 2012;188:5293–302.CrossRefPubMed
61.
62.
Jaeschke H, Farhood A, Bautista AP, Spolarics Z, Spitzer JJ, Smith CW. Functional inactivation of neutrophils with a Mac-1 (CD11b/CD18) monoclonal antibody protects against ischemia-reperfusion injury in rat liver. Hepatology. 1993;17:915–23.CrossRefPubMed
63.
Rogers C, Edelman ER, Simon DI. A mAb to the beta2-leukocyte integrin Mac-1 (CD11b/CD18) reduces intimal thickening after angioplasty or stent implantation in rabbits. Proc Natl Acad Sci USA. 1998;95:10134–9.PubMedCentralCrossRefPubMed
64.
Wilson I, Gillinov AM, Curtis WE, DiNatale J, Burch RM, Gardner TJ, et al. Inhibition of neutrophil adherence improves postischemic ventricular performance of the neonatal heart. Circulation. 1993;88(5 Pt 2):II372–9.PubMed
65.
Yonekawa K, Harlan JM. Targeting leukocyte integrins in human diseases. J Leukoc Biol. 2005;77:129–40.CrossRefPubMed
66.
67.
68.
Lum AF, Green CE, Lee GR, Staunton DE, Simon SI. Dynamic regulation of LFA-1 activation and neutrophil arrest on intercellular adhesion molecule 1 (ICAM-1) in shear flow. J Biol Chem. 2002;277:20660–70.CrossRefPubMed
69.
Ramamoorthy C, Sasaki SS, Su DL, Sharar SR, Harlan JM, Winn RK. CD18 adhesion blockade decreases bacterial clearance and neutrophil recruitment after intrapulmonary E. coli, but not after S. aureus. J Leukoc Biol. 1997;61:167–72.PubMed
70.
Gupta V. (2009). HTS identification of compounds that enhance the binding of CD11b/CD18 to fibrinogen via a luminescence assay. Pubchem Assay ID 1499.
71.
Faridi MH, Maiguel D, Barth CJ, Stoub D, Day R, Schürer S, Gupta V. Identification of novel agonists of the integrin CD11b/CD18. Bioorg Med Chem Lett. 2009;19:6902–6.PubMedCentralCrossRefPubMed
72.
Maiguel D, Faridi MH, Wei C, Kuwano Y, Balla KM, Hernandez D, Barth CJ, Lugo G, Donnelly M, Nayer A, Moita LF, Schürer S, Traver D, Ruiz P, Vazquez-Padron RI, Ley K, Reiser J, Gupta V. Small molecule-mediated activation of the integrin CD11b/CD18 reduces inflammatory disease. Sci Signal. 2011;4(189):ra57.PubMedCentralCrossRefPubMed
73.
Bordon Y. Immunotherapy: Leukadherins get a grip on inflammation. Nat Rev Immunol. 2011;11:638.CrossRefPubMed
74.
Faridi MH, Altintas MM, Gomez C, Duque JC, Vazquez-Padron RI, Gupta V. Small molecule agonists of integrin CD11b/CD18 do not induce global conformational changes and are significantly better than activating antibodies in reducing vascular injury. Biochim Biophys Acta. 2013;1830:3696–710.PubMedCentralCrossRefPubMed
75.
Tourkova IL, Yurkovetsky ZR, Shurin MR, Shurin GV. Mechanisms of dendritic cell-induced T cell proliferation in the primary MLR assay. Immunol Lett. 2001;78:75–82.CrossRefPubMed
76.
Rose S, Guevara P, Farach S, Adkins B. The key regulators of adult T helper cell responses, STAT6 and T-bet, are established in early life in mice. Eur J Immunol. 2006;36:1241–53.PubMedCentralCrossRefPubMed
77.
Rose S, Lichtenheld M, Foote M, Adkins B. Murine neonatal CD4 + cells are poised for rapid Th2 effector-like function. J Immunol. 2007;178:2667–78.PubMedCentralCrossRefPubMed
78.
Jurecic R, Van NT, Belmont JW. Enrichment and functional characterization of Sca-1+WGA+, Lin−WGA+, Lin−Sca-1+ and Lin−Sca-1+WGA+ bone marrow cells from mice with a Ly-6a haplotype. Blood. 1993;82:2673–83.PubMed
79.
Morrison SJ, Weissman IL. The long-term repopulating subset of hematopoietic stem cells is deterministic and isolatable by phenotype. Immunity. 1994;1:661–73.CrossRefPubMed
80.
Li CL, Johnson GR. Murine hematopoietic stem and progenitor cells: I. Enrichment and biologic characterization. Blood. 1995;85:1472–9.PubMed
81.
Christensen JL, Weissman IL. Flk-2 is a marker in hematopoietic stem cell differentiation: a simple method to isolate long-term stem cells. PNAS. 2001;98:14541–6.PubMedCentralCrossRefPubMed
82.
Adolfsson J, Borge OJ, Bryder D, Theilgaard-Monch K, Astrand-Grundstrom I, Sitnicka E, Sasaki Y, Jacobsen SE. Upregulation of Flt3 expression within the bone marrow Lin(-)Sca1(+)c-kit(+) stem cell compartment is accompanied by loss of self-renewal capacity. Immunity. 2001;15:659–69.CrossRefPubMed
83.
Yang L, Bryder D, Adolfsson J, Nygren J, Månsson R, Sigvardsson M, Jacobsen SE. Identification of Lin(-)Sca1(+)kit(+)CD34(+)Flt3- short-term hematopoietic stem cells capable of rapidly reconstituting and rescuing myeloablated transplant recipients. Blood. 2005;105:2717–23.CrossRefPubMed
84.
Adolfsson J, Mansson R, Buza-Vidas N, Hultquist A, Liuba K, Jensen CT, Bryder D, Yang L, Borge OJ, Thoren LA, et al. Identification of Flt3+ lympho-myeloid stem cells lacking erythro-megakaryocytic potential a revised road map for adult blood lineage commitment. Cell. 2005;121:295–306.CrossRefPubMed
85.
Kiel MJ, Yilmaz OH, Iwashita T, Yilmaz OH, Terhorst C, Morrison SJ. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell. 2005;121(7):1109–21.CrossRefPubMed
86.
Zayas J, Spassov DS, Nachtman RG, Jurecic R. Murine hematopoietic stem cells and multipotent progenitors express truncated intracellular form of c-kit receptor. Stem Cells Dev. 2008;17:343–53.PubMedCentralCrossRefPubMed
87.
Kiel MJ, Yilmaz OH, Morrison SJ. CD150- cells are transiently reconstituting multipotent progenitors with little or no stem cell activity. Blood. 2008;111(8):4413–4.PubMedCentralCrossRefPubMed
88.
Morita Y, Ema H, Nakauchi H. Heterogeneity and hierarchy within the most primitive hematopoietic stem cell compartment. J Exp Med. 2010;207:1173–82.PubMedCentralCrossRefPubMed
89.
Simon G, et al. Murine antithymocyte globulin therapy alters disease progression in NOD mice by a time-dependent induction of immunoregulation. Diabetes. 2008;57:405–14.CrossRefPubMed
Metadaten
Titel
New therapeutic approaches for protecting hematopoietic stem cells in aplastic anemia
verfasst von
Wendy Weston
Vineet Gupta
Rebecca Adkins
Roland Jurecic
Publikationsdatum
01.12.2013
Verlag
Springer US
Erschienen in
Immunologic Research / Ausgabe 1-3/2013
Print ISSN: 0257-277X
Elektronische ISSN: 1559-0755
DOI
https://doi.org/10.1007/s12026-013-8449-0

Weitere Artikel der Ausgabe 1-3/2013

Immunologic Research 1-3/2013 Zur Ausgabe

Immunology & Microbiology in Miami

Virulence regulons of enterotoxigenic Escherichia coli

Immunology & Microbiology in Miami

Insights into thymic involution in tumor-bearing mice

Guest Editorial

Immunology and microbiology in Miami

Immunology & Microbiology in Miami

Myeloid derived suppressor cells in physiological and pathological conditions: the good, the bad, and the ugly

Immunology & Microbiology in Miami

Molecular studies and therapeutic targeting of Kaposi’s sarcoma herpesvirus (KSHV/HHV-8) oncogenesis

Immunology & Microbiology in Miami

Alterations in macrophages and monocytes from tumor-bearing mice: evidence of local and systemic immune impairment

Neu im Fachgebiet HNO

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

29.05.2024 Hörstörungen Nachrichten

Hört jemand im Alter schlecht, nimmt das Hirn- und Hippocampusvolumen besonders schnell ab, was auch mit einem beschleunigten kognitiven Abbau einhergeht. Und diese Prozesse scheinen sich unabhängig von der Amyloidablagerung zu ereignen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen
Bildnachweise